AAV-GBA1 gene therapy for Parkinson's disease

被引：0
|
作者：
Glajch, K. E. [1 ]
Apicco, D. J. [1 ]
Chen, Y. [1 ]
Campbell, A. C. [1 ]
Hronowski, X. [1 ]
Hirst, W. D. [1 ]
机构：
[1] Biogen, Cambridge, MA USA
来源：
HUMAN GENE THERAPY | 2018年 / 29卷 / 12期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P198
引用
收藏
页码：A86 / A86
页数：1
相关论文
共 50 条
  • [1] GBA1-Linked Parkinson's Disease AAV Gene Therapy
    Toldra, Raquel Nunez
    Dimokov, Alex
    Bujor, Eliza
    Podda, Silvia
    Rahimnashat, Parisa
    Dodev, Tihomir
    Chew, Su Kit
    Buono, Mario
    Dastidar, Nisha Nair
    McNeill, Eileen
    Stennicke, Henning
    Sheridan, Rose
    MOLECULAR THERAPY, 2024, 32 (04) : 531 - 531
  • [2] Development of AAV-GBA1 Gene Replacement Therapy for IV Delivery via Blood Brain Barrier Penetrant AAV Capsid
    Chung, Charlotte
    Murlidharan, Giri
    Jagtap, Smita
    Adeluyi, Adewale
    Knoll, Elisabeth
    Ecker, Abigail
    Ezell, Brian
    Athanasopoulos, Tatiana
    Hoffman, Brett
    Knox, Tatiana
    Tocci, Jenna
    Peterson, Emalee
    Sayed-Zahid, Ambreen
    Paranjpe, Maneesha
    Grant, Kyle
    Bales, Kelly
    Carter, Todd
    MOLECULAR THERAPY, 2022, 30 (04) : 268 - 268
  • [3] Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations
    Abeliovich, Asa
    Hefti, Franz
    Sevigny, Jeffrey
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S183 - S188
  • [4] Development of AAV-GBA1 Gene Replacement Therapy via Single-IV-Delivery with a Blood Brain Barrier Penetrant AAV Capsid
    Chung, Charlotte
    Retzlaff, Cassie
    Thompson, Jeff
    Bloedel, Alexis
    Bruce, Amy
    Ecker, Abigail
    Clement, Joseph
    Knoll, Elisabeth R.
    Ezell, Brian C.
    Hoffman, Brett
    Knox, Tatiana
    Nonnenmacher, Mathieu E.
    Moyer, Tyler
    Lin, Jing
    Grant, Kyle
    Paranjpe, Maneesha
    Pande, Nilesh
    Johnson, Amy
    Yao, Johnny
    Sadhu, Chanchal
    Carter, Todd A.
    MOLECULAR THERAPY, 2023, 31 (04) : 347 - 347
  • [5] Gene therapy for Parkinson's disease using AAV vectors
    Ozawa, K
    Muramatsu, S
    Fujimoto, K
    Ikeguchi, K
    Shen, Y
    Wang, LJ
    Okada, T
    Mizukami, H
    Hanazono, Y
    Kume, A
    Ichinose, H
    Nagatsu, T
    Terao, K
    Nakano, I
    MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 459 - 462
  • [6] Development of an AAV-GBA Gene Therapy for the Treatment of Type 1 Gaucher Disease
    Cheng, Ting-Wen
    Souza, David
    Tabet, Ricardos
    Wright, Katherine
    Brodfuehrer, Joanne
    Keyes, Lisa
    Rao-Dayton, Sheila
    Lewis, Patricia
    Sievers, Annette
    McCarty, Douglas M.
    Somanathan, Suryanarayan
    Pan, Clark
    Bell, Robert D.
    MOLECULAR THERAPY, 2021, 29 (04) : 251 - 251
  • [7] AAV-GAD gene therapy for advanced Parkinson's disease
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) : 766 - 767
  • [8] AAV2-GDNF Gene Therapy for Parkinson's Disease
    Ram, Sharona Even
    Galun, Eithan
    HUMAN GENE THERAPY, 2009, 20 (05) : 430 - 431
  • [9] Design of Phase 1/2a Study of AAV9-Based Gene Therapy for Parkinson's Disease with Pathogenic GBA1 Mutations (PROPEL Trial)
    Uspenskaya, Olga
    Mahoney, Erin
    Verselis, Lynne
    Lowrey, Mark
    Velaga, Jenny
    Sevigny, Jeffrey
    NEUROLOGY, 2020, 94 (15)
  • [10] GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy
    Huh, Young Eun
    Usnich, Tatiana
    Scherzer, Clemens R.
    Klein, Christine
    Chung, Sun Ju
    JOURNAL OF MOVEMENT DISORDERS, 2023, 16 (03) : 261 - 278
12345